Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
ACA, Appeal, ascending, BLA, bribery, budget, captured, cell, congressional, constitutionality, Corrupt, House, implicated, inauguration, instance, instructing, leaving, lung, maximum, methodology, NSCLC, October, Orphan, passage, petition, presidential, prorated, PTO, quicker, ran, released, repeal, resolution, Senate, step, Supreme, tolerability, tolerated, Trump, unbeknownst, underlying, undertaken, unsubstantiated, upheld, variable, waive
Removed:
April, forfeiture, marketability, PPACA, preissuance, Relief, Taxpayer, valuation
Filing tables
Filing exhibits
CKPT similar filings
Filing view
External links
Exhibit 32.2
Certification of
Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Garrett Gray, Principal Financial Officer of Checkpoint Therapeutics, Inc. (the “Company”), in compliance with Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2017 (the “Report”) filed with the Securities and Exchange Commission:
• | Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
• | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Garrett Gray | |
Garrett Gray | |
Vice President, Finance and Accounting | |
(Principal Financial Officer) | |
November 3, 2017 |